শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে
🌐 View in English

ইঙ্গিত

Cancer

First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.Maintenance treatment of patients with locally advanced or metastatic NSCLC whose ... Read moreFirst-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum based first-line chemotherapy.Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

Pregnancy & Breastfeeding

Pregnancy category D. Erlotinib's mechanism of action suggests it can harm a developing fetus if taken during pregnancy. Whether Erlotinib passes into human breast milk is not known. Since many medicines do pass into breast milk, and because of the risk of serious side effects in a nursing infant, a decision should be made about whether to stop breastfeeding or stop the medicine, weighing how important it is for the mother's treatment.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: NSCLC: The recommended daily dose of Erlotinib for NSCLC is 150 mg, taken on an empty stomach, that is, at least one hour before or two hours after eating. Treatment should continue until the disease progresses or unacceptable toxicity occurs. Pancreatic Cancer: The recommended daily dose of Erlotinib for pancreatic cancer is 100 mg, taken once daily in combination with gemcitabine. Take Erlotinib on an empty stomach, that is, at least one hour before or two hours after eating. Treatment should continue until the disease progresses or unacceptable toxicity occurs. Reduce Erlotinib in 50 mg decrements if severe reactions occur with concomitant use of strong CYP3A4 inhibitors (such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, or grapefruit or grapefruit juice) or when used concomitantly with an inhibitor of both CYP3A4 and CYP1A2 (for example, ciprofloxacin). Increase Erlotinib in 50 mg increments as tolerated for concomitant use with CYP3A4 inducers, such as rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John's Wort. Increase doses in 50 mg increments at 2 week intervals to a maximum of 450 mg. Avoid concomitant use if possible. Concurrent cigarette smoking: Increase in 50 mg increments at 2 week intervals to a maximum of 300 mg. Immediately reduce the dose of Erlotinib to the recommended dose (150 mg or 100 mg daily) upon cessation of smoking.

পার্শ্বপ্রতিক্রিয়া ও পারস্পরিক ক্রিয়া

পার্শ্বপ্রতিক্রিয়া

No side-effect data recorded yet.